Site icon pharmaceutical daily

Proteomics Markets Technologies, and Competitive Landscape Report 2021 Featuring Profiles of 223 Players & 444 Respective Collaborations – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Proteomics – Technologies, Markets and Companies” report from Jain PharmaBiotech has been added to ResearchAndMarkets.com’s offering.

This report describes and evaluates the proteomic technologies that will play an important role in drug discovery, molecular diagnostics and practice of medicine in the post-genomic era.

Markets for proteomic technologies are analyzed for the year 2020 and are projected to years 2024 and 2030. The largest expansion will be in bioinformatics and protein biochip technologies. Important areas of application are cancer and neurological disorders.

The most commonly used technologies are 2D gel electrophoresis for protein separation and analysis of proteins by mass spectrometry. Microanalytical protein characterization with multidimensional liquid chromatography/mass spectrometry improves the throughput and reliability of peptide mapping. Matrix-Assisted Laser Desorption Mass Spectrometry (MALDI-MS) has become a widely used method for the determination of biomolecules including peptides, proteins.

Functional proteomics technologies include yeast two-hybrid system for studying protein-protein interactions. Establishing a proteomics platform in the industrial setting initially requires the implementation of a series of robotic systems to allow a high-throughput approach for analysis and identification of differences observed on 2D electrophoresis gels.

Protein chips are also proving to be useful. Proteomic technologies are now being integrated into the drug discovery process as complementary to genomic approaches. Toxicoproteomics, i.e. the evaluation of protein expression for understanding of toxic events, is an important application of proteomics in preclinical drug safety. The use of bioinformatics is essential for analyzing the massive amount of data generated from both genomics and proteomics.

Proteomics is providing a better understanding of pathomechanisms of human diseases. Analysis of different levels of gene expression in healthy and diseased tissues by proteomic approaches is as important as the detection of mutations and polymorphisms at the genomic level and may be of more value in designing a rational therapy.

Protein distribution/characterization in body tissues and fluids, in health as well as in disease, is the basis of the use of proteomic technologies for molecular diagnostics. Proteomics will play an important role in medicine of the future which will be personalized and will combine diagnostics with therapeutics. Important areas of application include cancer (oncoproteomics) and neurological disorders (neuroproteomics).

The number of companies involved in proteomics has increased remarkably during the past few years. More than 300 companies have been identified to be involved in proteomics and 223 of these are profiled in the report with 444 collaborations.

The markets for proteomic technologies are difficult to estimate as they are not distinct but overlap with those of genomics, gene expression, high throughput screening, drug discovery and molecular diagnostics.

Key Topics Covered:

Part I: Technologies and Markets

Executive Summary

1. Basics of Proteomics

2. Proteomic Technologies

3. Protein biochip technology

4. Bioinformatics in Relation to Proteomic

5. Research in Proteomics

6. Pharmaceutical Applications of Proteomics

7. Application of Proteomics in Human Healthcare

8. Oncoproteomics

9. Neuroproteomics

10. Proteomics Markets

11. Future of Proteomics

12. References

Part II: Companies

13. Companies involved in developing proteomics

For more information about this report visit https://www.researchandmarkets.com/r/8m0dga

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version